Three consecutive commercial-scale drug product batches successfully produced Supports potential sozinibercept BLA filing in 1H CY2026 MELBOURNE, ...

Manipulating the immune system to treat cancer has generated phenomenal responses in some patients, including complete cures, ...

US-based biotechnology company Inceptor Bio has dosed the first subject in the investigator-initiated trial of its lead ...

Q4 2024 Earnings Call Transcript February 24, 2025 BioCryst Pharmaceuticals, Inc. misses on earnings expectations. Reported ...

Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...

Operator Good morning, and welcome to the BioCryst fourth-quarter 2024 earnings call. All participants will be in listen-only mode. [Operator instructions] Please note this event is being recorded. I ...

Summit’s PD-1 bispecific antibody outperformed MSD’s Keytruda in a Phase III trial enrolling patients with lung cancer.

Ottimo Pharma ("Ottimo"), an innovative biotech company developing one-of-a-kind PD1/VEGFR2 dual pathway antibodies to extend the lives ...

PST-611, a first in class non-viral vectorized therapy expressing human transferrin, a highly potent iron regulator.

ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)——FY 2025 ORLADEYO ...

Retinal gene therapy advancements may rewrite the book on treatments for age-related macular degeneration and diabetic eye diseases.

Poor eyesight is a common problem, especially as one becomes older. Is there a way to check macular degeneration in the eyes, ...